Results aren't instant
It can also help break weight plateaus caused by metabolic resistance
Fighting against depression with TREK-1 blockers: Past and future
Back to Journals Vascular Health and Risk Management Volume 12 SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives Authors Gurgle H, White K, McAdam-Marx C Received 14 November 2015 Accepted for publication 11 March 2016 Published 4 June 2016 Volume 2016:12 Pages 239249 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 5 Editor who approved publication: Dr Daniel Duprez Holly E Gurgle, Karen White, Carrie McAdam-Marx Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA Abstract: Controversy exists regarding the selection of second-line therapy for patients with type 2 diabetes mellitus (T2DM) who are unable to achieve glycemic control with metformin therapy alone
Conclusions In this real-world cohort of adults with overweight or obesity without diabetes, liraglutide, semaglutide, and tirzepatide were all associated with clinically meaningful weight loss and favorable metabolic effects over 36 weeks of treatment
(*) Lu , nn c s tham kho ca chuyn gia
